From the University of South Florida Morsani College of Medicine, Tampa (T.B.C.); and the University of North Carolina at Chapel Hill School of Medicine, Chapel Hill (A.W.B.).
Caren G. Solomon, M.D., M.P.H., Editor
Address reprint requests to Dr. Casale at the Division of Allergy and Immunology, University of South Florida Morsani College of Medicine, 2901 Bruce B. Downs Blvd., MDC 19, Tampa, FL 33612, or at [email protected].
Dr. Casale reports receiving consulting fees from Stallergenes and consulting fees to his institution from Genentech and Novartis; grant support from Novartis, Genentech, ALK-Albello, Merck, and Stallergenes; and lecture fees from ALK-Albello. Dr. Burks reports receiving consulting fees from Abbott Laboratories, McNeil Nutritionals, and Gerson Lehrman Group Research; serving as an unpaid consultant for Dow AgroSciences, Merck, Novartis, Schering-Plough, Unilever, ExploraMed Development, Nordic Biotech Advisors, Nutricia North America, Perrigo, Portola Pharmaceuticals, Regeneron Pharmaceuticals, and Perosphere; owning stock in Allertein Therapeutics and Mast Cell Pharmaceuticals; and giving an unpaid lecture for Mylan Specialty. No other potential conflict of interest relevant to this article was reported.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
